Den europeiske union - engelsk - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukemia, myeloid - antineoplastic agents - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.

Den europeiske union - engelsk - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - immunosuppressants - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).

Den europeiske union - slovakisk - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukémia, myeloid - antineoplastické činidlá - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.

Den europeiske union - ungarsk - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukémia, mieloid - daganatellenes szerek - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.

Den europeiske union - slovakisk - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - tolvaptan - polycystický oblićok, autozomálne dominantné - diuretiká, - jinarc je indikovaný na spomalenie postupu rozvoja cýst a obličkovej nedostatočnosti autozomálne dominantné polycystické ochorenie obličiek (adpkd) u dospelých pacientov s ckd fázy 1 až 3 na začiatku liečby s preukázaným rýchlo postupujúce ochorenie,.

Den europeiske union - slovakisk - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - tolvaptan - nevhodný syndróm adh - diuretiká, - liečba dospelých pacientov s hyponatriémiou sekundárnou k syndrómu nevhodnej sekrécie antidiuretického hormónu (siadh).

Den europeiske union - slovensk - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leukemija, myeloid - antineoplastična sredstva - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.

Den europeiske union - ungarsk - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - tolvaptan - policisztás vese, autoszomális domináns - vizelethajtók, - jinarc jelzi, hogy lassú a haladás, a fejlődés ciszta és veseelégtelenségben autoszomális domináns policisztás vesebetegség (adpkd) a felnőttek ckd stage 1-3 kezelés megkezdésekor bizonyítékokat gyorsan halad betegség,.

Den europeiske union - ungarsk - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - tolvaptan - nem megfelelő adh-szindróma - vizelethajtók, - a nem megfelelő antidiuretikus hormon szekréciót (siadh) szekunder másodlagos hyponatraemia kezelésben részesülő felnőtt betegek kezelése.

Den europeiske union - slovakisk - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - imunosupresíva - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).